Frencken Group's Likely Revenue Growth in 1H May Outperform Industry -- Market Talk

Dow Jones

May 26

0151 GMT - Frencken Group's likely revenue growth in 1H, driven by its semiconductor and medical segments, may outperform the industry, UOB Kay Hian's John Cheong says in a research report. The technology solutions provider has a cautiously optimistic stance and expects moderate revenue growth in 1H 2025 versus 2H 2024, the analyst notes. The Singapore-listed company also doesn't expect significant impact from U.S. tariffs, given shipments to the U.S. accounted for only around 9% of its revenue in 2024. The brokerage lifts its price-to-earnings multiple peg to 15x from 12.5x to reflect Frencken's ability to outperform peers. It raises the stock's target price to S$1.40 from S$1.16 with an unchanged buy rating. Shares are unchanged at S$1.13. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

May 25, 2025 21:51 ET (01:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2538147949"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538147949\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538147949?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-26 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538147949","market":"other","top_or_hot":-1,"title":"Frencken Group's Likely Revenue Growth in 1H May Outperform Industry -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0151 GMT - Frencken Group's likely revenue growth in 1H, driven by its semiconductor and medical segments, may outperform the industry, UOB Kay Hian's John Cheong says in a research report. The technology solutions provider has a cautiously optimistic stance and expects moderate revenue growth in 1H 2025 versus 2H 2024, the analyst notes. The Singapore-listed company also doesn't expect significant impact from U.S. tariffs, given shipments to the U.S. accounted for only around 9% of its revenue in 2024. The brokerage lifts its price-to-earnings multiple peg to 15x from 12.5x to reflect Frencken's ability to outperform peers. It raises the stock's target price to S$1.40 from S$1.16 with an unchanged buy rating. Shares are unchanged at S$1.13. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 25, 2025 21:51 ET (01:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Frencken Group's Likely Revenue Growth in 1H May Outperform Industry -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrencken Group's Likely Revenue Growth in 1H May Outperform Industry -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-26 09:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0151 GMT - Frencken Group's likely revenue growth in 1H, driven by its semiconductor and medical segments, may outperform the industry, UOB Kay Hian's John Cheong says in a research report. The technology solutions provider has a cautiously optimistic stance and expects moderate revenue growth in 1H 2025 versus 2H 2024, the analyst notes. The Singapore-listed company also doesn't expect significant impact from U.S. tariffs, given shipments to the U.S. accounted for only around 9% of its revenue in 2024. The brokerage lifts its price-to-earnings multiple peg to 15x from 12.5x to reflect Frencken's ability to outperform peers. It raises the stock's target price to S$1.40 from S$1.16 with an unchanged buy rating. Shares are unchanged at S$1.13. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 25, 2025 21:51 ET (01:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"E28.SI","symbol_name":"福根集团有限公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2538147949","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538147949","pubTimestamp":1748224260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0151 GMT - Frencken Group's likely revenue growth in 1H, driven by its semiconductor and medical segments, may outperform the industry, UOB Kay Hian's John Cheong says in a research report. The technology solutions provider has a cautiously optimistic stance and expects moderate revenue growth in 1H 2025 versus 2H 2024, the analyst notes. The Singapore-listed company also doesn't expect significant impact from U.S. tariffs, given shipments to the U.S. accounted for only around 9% of its revenue in 2024. The brokerage lifts its price-to-earnings multiple peg to 15x from 12.5x to reflect Frencken's ability to outperform peers. It raises the stock's target price to S$1.40 from S$1.16 with an unchanged buy rating. Shares are unchanged at S$1.13. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"E28.SI":"福根集团有限公司"},"translate_title":"Frencken集团上半年收入增长可能跑赢行业——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"E28.SI":1},"content_text":"0151 GMT - Frencken Group's likely revenue growth in 1H, driven by its semiconductor and medical segments, may outperform the industry, UOB Kay Hian's John Cheong says in a research report. The technology solutions provider has a cautiously optimistic stance and expects moderate revenue growth in 1H 2025 versus 2H 2024, the analyst notes. The Singapore-listed company also doesn't expect significant impact from U.S. tariffs, given shipments to the U.S. accounted for only around 9% of its revenue in 2024. The brokerage lifts its price-to-earnings multiple peg to 15x from 12.5x to reflect Frencken's ability to outperform peers. It raises the stock's target price to S$1.40 from S$1.16 with an unchanged buy rating. Shares are unchanged at S$1.13. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 25, 2025 21:51 ET (01:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}